RXII - RXi Pharmaceuticals Corporation

YHD - YHD Delayed Price. Currency in USD
At close: 6:07PM EDT
Stock chart is not supported by your current browser
Previous CloseN/A
YTD ReturnN/A
Expense Ratio (net)N/A
CategoryN/A
Last Cap GainN/A
Morningstar RatingN/A
Morningstar Risk RatingN/A
Sustainability RatingN/A
Net AssetsN/A
Beta (3Y Monthly)N/A
YieldN/A
5y Average ReturnN/A
Holdings TurnoverN/A
Last DividendN/A
Average for CategoryN/A
Inception DateN/A
  • PR Newswire

    Phio Pharmaceuticals Appoints Gerrit Dispersyn as New Chief Executive Officer Effective March 1

    MARLBOROUGH, Mass., Feb. 15, 2019 /PRNewswire/ -- Phio Pharmaceuticals Corp. (PHIO) today announced that Gerrit Dispersyn, Dr. Med. Sc., currently President and COO, has been appointed by the Board of Directors as the Company's new CEO, effective March 1.

  • Zacks Small Cap Research

    PHIO: Soldiering On as We Wait for Bids

    PHIO Pharmaceuticals Corp. (PHIO) reported third quarter results and filed its Form 10-Q on November 14, 2018. Patent awards, collaborations, pre-clinical advances in the immuno-oncology programs and a financing that opens a runway until 2020 rounded out other key events from June 30 to date. In conjunction with the third quarter release, the company changed its name to PHIO Pharmaceuticals and its ticker symbol to PHIO.

  • GlobeNewswire

    Report: Exploring Fundamental Drivers Behind Pluristem Therapeutics, RXi Pharmaceuticals, Saga Communications, Global Self Storage, Sequential Brands Group, and Finjan — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Nov. 19, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Thomson Reuters StreetEvents

    Edited Transcript of RXII earnings conference call or presentation 14-Nov-18 9:30pm GMT

    Q3 2018 Rxi Pharmaceuticals Corp Earnings Call

  • ACCESSWIRE

    4 Healthcare Stocks To Watch On Wednesday

    CORAL GABLES, FL / ACCESSWIRE / November 14, 2018 / Healthcare demand is increasing as an aging population continues to drive new healthcare market growth. The connection between healthcare goods and services is less tied to the economy compared to other sectors, and that could make healthcare stocks the place where investors will look for a hedge as the broader markets see increasing volatility. According to Bureau of Labor Statistics data*, the fastest-growing sectors include healthcare support occupations (23.2% increase from 2016-2026) and healthcare practitioners and technical occupations (15.2%), which entail home health aides, physician assistants and nurse practitioners, among other positions.

  • PR Newswire

    RXi Pharmaceuticals Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights

    - Appoints Gerrit Dispersyn as President and Chief Operating Officer, effective Today - Geert Cauwenbergh to Remain CEO and Member of Board of Directors - Announces Planned Change in Company Name from ...

  • PR Newswire

    RXi Pharmaceuticals to Present New Data Demonstrating the Ability of sd-rxRNA to Enhance NK Cell Activity for Adoptive Cell Transfer at SITC 2018

    MARLBOROUGH, Mass. , Nov. 7, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary ...

  • Biotech RXi sues former top scientist for alleged trade secrets theft
    American City Business Journals

    Biotech RXi sues former top scientist for alleged trade secrets theft

    In the suit, which was filed in federal court on Oct. 19, the biotech claims that its former chief scientific officer downloaded its proprietary scientific data before leaving the company in 2012.

  • Zacks Small Cap Research

    RXII: Dilution Impact from Share Issuance

    On October 3rd, 2018 RXi Pharmaceuticals Corp. (RXII) announced it had closed its $15 million public underwriting. 3.725 million shares were issued at $0.70 per share and 17.702 million prefunded warrants were issued at $0.69 per share with a $0.01 exercise price. 21.427 million seven year warrants were also issued with an exercise price of $0.70.

  • PR Newswire

    RXi Pharmaceuticals Announces Closing Of $15 Million Underwritten Public Offering

    MARLBOROUGH, Mass., Oct. 3, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform, today announced the closing of its previously announced underwritten public offering of 3,725,714 units at a public offering price of $0.70 per unit and 17,702,858 pre-funded units at a public offering price of $0.69 per pre-funded unit, raising gross proceeds of approximately $15 million. The Company intends to use the net proceeds of this offering towards the development of RXi's immuno-oncology program, for other research and development activities and for general working capital. Each unit sold in this offering contained one share of common stock and one warrant to purchase one share of common stock.

  • PR Newswire

    RXi Pharmaceuticals Announces Pricing Of $15 Million Upsized Underwritten Public Offering

    MARLBOROUGH, Mass., Oct. 1, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform, today announced the pricing of an underwritten public offering of 21,428,572 units at a price to the public of $0.70 per unit. Each unit contains one share of common stock (or common stock equivalent) and one warrant to purchase one share of common stock.

  • ACCESSWIRE

    Today's Research Reports on Stocks to Watch: RXi Pharmaceuticals and Geron

    NEW YORK, NY / ACCESSWIRE / September 28, 2018 / Rxi Pharmaceuticals saw its shares soaring on Thursday as the company presented a poster entitled, "The Use of Self-delivering RNAi to Enhance NK Cell Cytotoxicity," at the 16th Annual Discovery on Target Conference. Geron shares were going in the opposite direction and crashed hard after Wall Street learned that its collaboration with Johnson & Johnson has come to an end. RXi Pharmaceuticals Corporation shares were up a little over 28% at the close on Thursday.

  • PR Newswire

    RXi Pharmaceuticals to Present New Data from its Immuno-Oncology Program Using sd-rxRNA Therapeutic Compounds Targeting Intracellular Checkpoint Cbl-b in NK Cells at the 16th Annual Discovery on Target Conference

    - RXi to present a poster today, Wednesday, September 26, 2018 - Advancements in the Company's immuno-oncology programs will be presented demonstrating the potential of sd-rxRNA in NK cells for the use ...

  • Zacks Small Cap Research

    RXII: Dermal & Ocular Assets Available for Sale

    During the second quarter, RXi obtained additional financing to continue the development of its immuno-oncology program, provided readouts for Samcyprone and RXI-109 in retinal scarring and developed a research collaboration with autologous TIL leader, Iovance. The area of immediate interest is the status of the dermatology and ocular assets which have all provided data available for potential suitors to review. RXi is dependent on an upfront payment from these assets to support the oncology programs that are in development.